- Male or female outpatients >=18 years old
- Eligible for receiving Toviaz 4mg or 8mg QD treatment based on the approved US label.
- Female subjects who are pregnant, lactating, or who are intending to become pregnant
within 28 days after the completion of the study (use of contraceptives is not
required to participate in the study)
- Have participated in any other studies involving study drugs within 30 days prior to
entry in the study
- Subjects who have previously taken fesoterodine.